ICE Bioscience Posters

Download

Targeted protein degradation (TPD) harnesses the ubiquitin-proteasome system to eliminate disease drivers once deemed “undruggable”. PROTACs recruit E3 ligases to targets via two linked warheads, while monovalent molecular glue degraders (MGDs) induce novel ligase-substrate interactions and ternary complex formation. Preclinical success in targeting VAV1, STAT6, NEK7, IRAK4 etc. has demonstrated remarkable efficacy in rheumatoid arthritis, atopic dermatitis and other autoimmune models, positioning TPD as a transformative therapeutic modality.

ICE’s integrated platform accelerates TPD discovery through SpS-based high-throughput screening, targeted libraries and an end-to-end workflow from hit identification to in vivo validation. Our experience includes support for discovery of multiple MGDs and PROTACs—showcased here by discovery of a potential NEK7 MGD, and our integrated TPD platform including orthogonal biochemical and biophysics binding assays, comprehensive in vitro functional characterization, in depth MOA studies, in vivo model validation and safety evaluation. By delivering robust, actionable data at every stage, ICE empowers rapid advancement of next-generation autoimmune interventions.